Weill David purchased $109K of TMDX

Weill David purchased 1,336 shares of TransMedics Group, Inc. (TMDX) at $81.63 ($0.11M total) on 2026-09-11.

Original reporting
SEC EDGAR · Weill David
Published Sep 14, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMDX
Neutral
medium confidence
Mentioned
$TMDX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMDXNeutralLow
01

Why it matters

The insider buy is modest and unlikely to move the stock significantly, but it adds a data point for monitoring insider sentiment.

02

Market read

Primary insider transaction with limited market impact; useful for tracking but not a strong trading catalyst.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 6/10Timing: post-market 2026-09-11

Background

Form 4 filing reveals a director's recent open‑market purchase of TransMedics Group stock.

Company-level read

Ticker impact

$TMDXNeutralMedium confidence
Context

Director David Weill purchased 1,336 shares of TransMedics Group at $81.63 each, a $109K insider buy disclosed on Form 4.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The transaction size is modest relative to market cap and typical insider activity, reducing actionable significance.

Market effects

None significant for the broader medical device sector.

No notable regional effect.

Limited to investors tracking insider activity.

Counterpoint

The purchase could be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • TransMedics Group, Inc.

    Medical device company listed on NASDAQ.

  • David Weill

    Director of TransMedics Group.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.